Epigenetics Market - Top Companies and Manufacturers

In the News

• AbbVie - AbbVie, a leading biotech firm focused on cutting-edge research, announced that as of December 1st, 2021, VENCLEXTA® (venetoclax), a drug, is now included under the Pharmaceutical Benefits Scheme (PBS). This treatment is designated for adults battling a certain form of leukemia (acute myeloid leukemia or AML) who are unable to undergo intensive chemotherapy. AML is a rapidly spreading blood cancer impacting the bone marrow and blood system. In AML, the growth of abnormal leukemia cells outpaces healthy blood cells, hindering their essential functions, such as combating infections, oxygen transport, and bleeding control. Without prompt intervention, AML can cause severe infections and additional severe health issues.

• GlaxoSmithKline (GSK) - IDEAYA and GSK are joining forces to craft new cancer cures through a cutting-edge method named "synthetic lethality." IDEAYA contributes three projects (MAT2A, Pol Theta, and Werner Helicase) poised to reach clinical trial stages within the next few years. These initiatives are already off to a solid start, with both the 3D structures mapped out and promising early results from animal tests for two of them (MAT2A and Pol Theta). This partnership meshes well with GSK’s strategic priority of exploiting synthetic lethality in its quest to forge novel cancer therapies.